United States

Amgen Inc v Sanofi

598 US 594 (2023)

JurisdictionUnited States

Year2023

Statusunclear

Key Principle

The enablement requirement of 35 USC §112 demands that the patent specification enable the full scope of the claimed genus, not just a few species; broad functional claims to an entire genus of antibodies were invalid for lack of enablement.

Area of Law

Related Cases

Cantarella Bros Pty Ltd v Modena Trading Pty Ltd (2014) 254 CLR 337

Phonographic Performance Company of Australia Ltd v Commonwealth (2012) 246 CLR 561

Roadshow Films Pty Ltd v iiNet Ltd (2012) 248 CLR 42

Ask CommonBench about this case

Get a detailed analysis of Amgen Inc v Sanofi and how it applies to your situation.

Explain Amgen Inc v Sanofi